Prelude Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

Prelude Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-290,000	Closed	-$2.44M	–	2021
2021 Q2	$2.44M	Buy	+290,000	New	+$3.07M	0.07%	234
2020 Q2	–	Sell	-3,400	Closed	-$31K	–	2249
2020 Q1	$31K	Sell	3,400 -42,100	-93%	-$431K	﹤0.01%	877
2019 Q4	$446K	Hold	45,500	–	–	0.02%	593
2019 Q3	$313K	Hold	45,500	–	–	0.01%	649
2019 Q2	$420K	Sell	45,500 -4,500	-9%	-$54.3K	0.02%	537
2019 Q1	$784K	Buy	+50,000	New	+$882K	0.04%	389

Other funds holding TEVA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Prelude Capital Management's TEVA Position: Q1 2026 in Review

Prelude Capital Management increased its Teva Pharmaceuticals (TEVA) stake by 53% in Q1 2026, buying an estimated $1.72M and bringing the position to 154,970 shares worth $4.67M. The position accounts for 0.36% of the portfolio, ranked #57.

Prelude Capital Management first reported a position in TEVA in Q2 2014 and has held it in 26 quarters since. 651 funds tracked by Wall St. Rank hold TEVA as of Q1 2026.

Prelude Capital Management held 154,970 shares of Teva Pharmaceuticals worth $4.67M as of Q1 2026.
Prelude Capital Management bought 53,500 Teva Pharmaceuticals shares in Q1 2026, an estimated $1.72M.
Teva Pharmaceuticals made up 0.36% of Prelude Capital Management's portfolio in Q1 2026, its #57 holding.
Prelude Capital Management first reported a position in Teva Pharmaceuticals in Q2 2014 and has held it in 26 quarters since.
651 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2026.

Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.